PB2128: CLINICAL CONSENSUS ON FIRST-LINE (1L) TREATMENTS FOR TRANSPLANT-INELIGIBLE (TIE) PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): DELPHI PANEL OF US HEMATOLOGISTS AND ONCOLOGISTS

• Rafael Fonseca,
• Adriana Rossi,
• Jennifer Voelker,
• Trevor Homan,
• Shuchita Kaila,
• Rohan Medhekar,
• Jessica Wilcock,
• Anna Karakusevic,
• James Cochrane,
• Daisy Bridge,
• Richard Perry,
• Faith E Davies

Affiliations

Rafael Fonseca

1 Mayo Clinic, Division of Hematology/Oncology, Phoenix, United States

Adriana Rossi

2 Icahn School of Medicine, Mount Sinai, New York, United States

Jennifer Voelker

3 Janssen Scientific Affairs, LLC., Horsham, United States

Trevor Homan

3 Janssen Scientific Affairs, LLC., Horsham, United States

Shuchita Kaila

3 Janssen Scientific Affairs, LLC., Horsham, United States

Rohan Medhekar

3 Janssen Scientific Affairs, LLC., Horsham, United States

Jessica Wilcock

4 Adelphi Values PROVE, Bollington, United Kingdom

Anna Karakusevic

4 Adelphi Values PROVE, Bollington, United Kingdom

James Cochrane

4 Adelphi Values PROVE, Bollington, United Kingdom

Daisy Bridge

4 Adelphi Values PROVE, Bollington, United Kingdom

Richard Perry

4 Adelphi Values PROVE, Bollington, United Kingdom

Faith E Davies

5 Perlmutter Cancer Center, NYU Langone Health, New York, United States